Biogen (NasdaqGS:BIIB) has appointed Dr. Maria C. Freire as Chair of its Board of Directors. Dr. Freire brings experience in biomedical research, drug development, and public private partnerships. The ...
Biogen (NASDAQ:BIIB) outlined its immunology and neurology development priorities during a virtual symposium hosted by Piper ...
Eisai remains deeply committed to a patient-centered approach in Alzheimer's care and ensuring LEQEMBI (R) is available to those eligible and living with early AD in Canada. We will continue to pursue ...
GlobalData on MSN
FDA grants breakthrough status to Biogen’s litifilimab for CLE
The Phase III AMETHYST study is currently assessing litifilimab’s safety and efficacy, with results anticipated in 2027.
China granted Priority Review for an at-home Alzheimer’s treatment developed by Biogen and Eisai. ・If approved, the ...
Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous lupus erythematosus (CLE) skin disease activity ...
Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that there are many more steps before the Alzheimer’s therapy could reach the market ...
The uptick in Leqembi (lecanemab) sales comes a few months after the FDA approved a once-weekly subcutaneous injection version of the drug that can be used as an alternative to infusions during the ...
The Alzheimer's drug maker reported revenues of $2.28 billion, beating the consensus of $2.20 billion, down 7% on a reported and constant currency basis. Biogen on Friday said fiscal 2025 revenue from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results